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Growing evidence suggests that macrophage inflammatory protein (MIP)‑1alpha (synonym CCL3) is upregulated in the 
neuroinflammatory processes initiated by some brain disorders, but its precise role and regulatory mechanism remain unclear. The 
present work aims to evaluate the role of CCL3/MIP‑1alpha in lipopolysaccharide (LPS)‑induced brain injury, and investigate whether 
the MAPKs and NF‑kappaB regulate CCL3/MIP‑1alpha expression. We firstly examined the patterns of CCL3/MIP‑1alpha expression and 
phosphorylation of MAPKs in the brains of rats 6, 24, and 72 h after LPS administration. Additionally, LPS‑treated rats were administered 
an anti‑MIP‑1alpha neutralizing antibody, and the microglial reaction and the expression of both cyclooxygenase‑2 and inducible nitric 
oxide synthase (iNOS) were analyzed. We finally evaluated the effect of an inhibitor of P38 MAPK, an inhibitor of ERK1/2, or an inhibitor 
of NF‑kappaB, on the levels of CCL3/MIP‑1alpha protein and numbers of microglia in the brain. In the observation period, LPS induced 
CCL3/MIP‑1alpha expression, which localized to OX‑42‑labeled microglia, leading to time‑dependent increases in the phosphorylation 
of P38 MAPK and ERK1/2. The expression pattern of induced CCL3/MIP‑1alpha was partly consistent with the phosphorylation of MAPKs 
(P38 MAPK, ERK1/2). Anti‑MIP‑1alpha attenuated microglial accumulation and the upregulation of cyclooxygenase‑2 and iNOS. The 
inhibition of P38 MAPK, ERK1/2, or NF‑kappaB signaling reduced the induced upregulation of CCL3/MIP‑1alpha and the microglial 
accumulation. Our data suggest that upregulated CCL3/MIP‑1alpha mediates the accumulation of microglia and the neuroinflammatory 
reaction, and its expression may be regulated by MAPKs and NF‑kappaB in LPS‑induced brain injury.
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INTRODUCTION
Inflammatory processes are involved in a broad range 
of neuropathological conditions, which can be simulated 
experimentally with lipopolysaccharide (LPS) (Henry et al. 
2008, Lee et al. 2010), a polysaccharide component of the cell 
walls of Gram‑negative bacteria. LPS causes inflammatory 
responses in the central nervous system (CNS), characterized 
by production of inflammatory cytokines, glial activation, 
and neuronal damage (Qin et al. 2007, Henry et al. 2008, 
Tanaka et al. 2011). It is used widely in experimental 
systems to induce neuroinflammation. Chemokines 
are low‑molecular‑weight chemotactic cytokines that 
mediate the accumulation of leukocytes at the sites of 
inflammation (Luster 1998, Charo and Ransohoff 2006). 
The beta‑chemokines, a subfamily of chemokines, include 
monocyte chemoattractant protein (MCP)‑1 (synonym 
CCL2), macrophage inflammatory protein (MIP)‑1alpha 
(synonym CCL3), MIP‑1beta (synonym CCL4), etc., and have 
been implicated in the inflammatory processes in the CNS 
(Charo and Ransohoff 2006, Lenglet et al. 2014).
The biological effects of CCL2/MCP‑1 on the 
neuroinflammation caused by CNS diseases have been 
extensively investigated (Gerard and Rollins 2001, Hinojosa 
et al. 2011, Charo and Ransohoff 2006). The initial interest 
in the role of CCL3/MIP‑1alpha in neuroinflammation 
originated from a previous observation that the intravenous 
administration of LPS causes a time‑dependent increase 
in CCL3/MIP‑1alpha in the rat brain, hinting at a role in 
the neuroinflammatory response to infection (Gourmala 
et al. 1999). CCL3/MIP‑1alpha is upregulated in the CNS in 
experimental models of autoimmune encephalomyelitis 
(Karpus et al. 1995), traumatic brain injury (Israelsson et al. 
2014), and status epilepticus (Zhu et al. 2012). The deletion 
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of the CCL3/MIP‑1alpha gene reduced astrocytosis and 
microgliosis in the hippocampus after the administration 
of beta‑amyloid (1–40) (Passos et al. 2009). Another study, 
however, demonstrated that CCL3/MIP‑1alpha secreted 
by astrocytes promotes the differentiation of embryonic 
neuronal cells and has neuroprotective functions (Park et 
al. 2009). These contradictory data prompted us explore the 
role of CCL3/MIP‑1alpha in neuroinflammation in a model 
of LPS‑induced brain injury. 
We also examined the mechanisms regulating the 
induction of CCL3/MIP‑1alpha in response to LPS. 
LPS activates many signaling molecules, including 
mitogen‑activated protein kinases (MAPKs) (Guha and 
Mackman 2001, Uesugi et al. 2006) and transcription factors 
such as nuclear factor (NF)‑kappaB and activator protein 1 
(AP‑1) (Guha and Mackman 2001, Diks et al. 2004). MAPKs 
are one of the most important kinase families, and are 
major intracellular signal transduction factors that regulate 
the production of many cytokines and chemokines in the 
CNS (Pearson et al. 2001, Kim and Choi 2010). In cultured 
microglia, activated extracellular signal‑regulated kinase 
1/2 (ERK1/2), c‑Jun N‑terminal kinase (JNK), and P38 MAPK 
regulate the expression of CCL3/MIP‑1alpha after external 
stimulation, such as by S100B or monoclonal antibody‑coated 
Cryptococcus neoformans immune complexes (Song et al. 
2002, Soares et al. 2009). Matsuyama and others (2004) also 
reported that collagen induced the expression of CCL3/
MIP‑1alpha in human macrophages in a P38 MAPK‑ and 
NF‑kappaB‑dependent manner. However, a recent study 
showed that the induction of both CCL3/MIP‑1alpha and 
CCL2/MCP‑1 by lipoteichoic acid is regulated by ERK1/2 and 
JNK, rather than by the P38 MAPK signaling molecule, in 
murine macrophages (Park et al. 2013).
In this study, we examined the expression and role 
of CCL3/MIP‑1alpha in the brains of rats subjected 
to intracerebroventricular (i.c.v.) LPS injection, and 
determined the roles of the MAPK and NF‑kappaB 
signaling molecules in the upregulated expression of CCL3/
MIP‑1alpha. Our findings indicate that upregulated CCL3/
MIP‑1alpha contributes to the accumulation of microglia 
and mediates the inflammatory response to LPS in the 
brain. Furthermore, the expression of CCL3/MIP‑1alpha 
might be regulated by the activated P38 MAPK, ERK1/2, 
and NF‑kappaB signaling molecules. The results of this 
study extend our understanding of CCL3/MIP‑1alpha as 
a therapeutic target for neuroinflammation.
METHODS 
Animals
Adult wistar rats weighing 180–200 g were purchased 
from the Experimental Animal Center, Shandong University. 
They were housed in plastic cages with free access to water 
and food, and maintained in a temperature‑controlled 
(22–24°C) room with a fixed 12 h light‑dark cycle. All 
experiments were conducted in compliance with the 
National Institutes of Health Guidelines and the legal 
requirements in China. The protocol was approved by 
the Ethics Committee on Animal Experiments of Medical 
School of Shandong University. We made our efforts to 
reduce the number of animals used and their suffering in 
experiments.
Surgical preparation
Surgical Operation of rats was performed as described 
by Soares and others (2009), with slight adjustment from the 
stereotaxic coordinates of rat brain (Paxinos and Watson 
2004). In brief, under anesthetized with chloral hydrate 
(400 mg/kg, i.p.), rats were placed in a stereotaxic apparatus 
to implant a stainless steel guide cannula (22‑gauge, 
0.8 mm OD, 10 mm length) for drug administration into 
the right lateral ventricle at the following stereotaxic 
coordinates: 1.2 mm posterior, 1.6 mm lateral, and 2.5 mm 
deep relative to the bregma. This cannula was fixed to the 
skull with stainless steel screws and dental acrylic cement. 
Seven days after surgery, all rats were randomly divided 
into the subsequent experiments.
Experimental protocols
In the first set of experiment, rats were i.c.v. injected 
with LPS (0.2 mg/kg BW, Escherichia coli serotype 055:B5, 
Sigma, USA) at a concentration of 50 mg/ml. Administration 
was performed through an inner cannula connected to 
5 μl Hamilton microsyringe at the rate of 1 μl/min. The 
dose of LPS was chosen based on the optimal responses 
in preliminary experiments and the results reported by 
Tyagi and others (2010). Rats were sacrificed at 6, 24 and 
72 h after administration. The control rats were injected 
with the equal volume of saline and sacrificed at 24 h after 
injection. Brains were collected for immunohistochemistry 
(n=6 at each time point) or dissected to collect cerebral 
hemispheres for enzyme‑linked immunosorbent assay 
(ELISA) (n=4 at each time point) and Western blot (n=4 at 
each time point).
In the second experiment, LPS‑treated rats were i.c.v. 
injected with 5 ng anti‑MIP‑1alpha antibody (Abcam, 
USA) or normal immunoglobulin G (IgG) (Serotec, UK) in 
a volume of 1 μl sterile saline immediately and 12 h after 
LPS administration. The saline control rats were injected 
twice with the equal volume of IgG. Rats were divided into 
the following groups: Saline+IgG rats, LPS+IgG rats, and 
LPS+anti‑MIP‑1alpha rats. The dose of anti‑MIP‑1alpha 
5_903_Zhu_v4.indd   305 27/12/16   16:12
306 X. Zhu et al. Acta Neurobiol Exp 2016, 76: 304–317
was chosen on the basis of the results of preliminary 
experiments and the data of Soares and colleagues (2009). 
Rats were anesthetized and sacrificed at 24 and 72 h after 
injection. Brains were collected for immunohistochemistry 
(n=6 per group), or dissected to collect hippocampus and 
prefrontal cortex for Western blot (n=4 per group). 
In the third experiment, LPS‑treated rats were i.c.v 
injected with P38 MAPK inhibitor SB203580 (0.5 mM/kg, 
Cell Signaling Technology, USA), ERK1/2 inhibitor PD98059 
(2.5 mM/kg, Cell Signaling Technology) dissolved in 2 μl 
diluted dimethyl sulfoxide (DMSO) (ZSGB‑BIO, China) in 
a range of 5–15%, or 5% NF‑kappaB inhibitor pyrrolidine 
dithiocarbamate (PDTC) (Calbiochem, USA) in 2 μl sterile 
saline, 30 min prior to LPS administration. The same 
volume of 15% DMSO or sterile saline as a vehicle was 
also i.c.v. infused into LPS‑treated or saline control rats. 
Rats were divided into the following groups: Saline+DMSO 
rats, LPS+DMSO rats, LPS+Saline rats, LPS+SB203580 
rats, LPS+PD98059 rats, and LPS+PDTC rats. The doses of 
SB203580 and PD98059 were determined according to the 
results of previous studies by Sugino and others (2000) 
and Etgen and Acosta‑Martinez (2003), and PDTC were 
determined by the results of preliminary experiments 
and the data of Nurmi and colleagues (2004). Rats were 
sacrificed at 12h for real‑time polymerase chain reaction 
(PCR) (n=4 per group) and 24 h for immunohistochemistry 
(n=6 per group), Western blot (n=4 per group), or ELISA 
(n=4 per group) after LPS injection. 
Tissue collection and preparation
Rats were anesthetized and brain tissues were collected 
at the indicated time‑points. For molecular studies, 
rats were scarified and brains were rapidly removed 
from the skull. The dissected tissues were frozen in 
liquid nitrogen and stored at −80°C for later analysis. 
For immunohistochemical analysis, rats were perfused 
with 4% paraformaldehyde and brains were rapidly 
removed, immersed, and embedded with optimal cutting 
temperature compound. Coronal sections were obtained 
at the bregma level from 1.2 to −0.4 mm and from −2.5 to 
−3.8 mm, cut at a thickness of 20 μm (1‑in‑6 series, 120 μm 
apart from each other) with a sliding microtome (Leica 
Instruments, Germany), and collected on gelatin‑coated 
microscope slides stored at −20°C.
ELISA assay
The brain tissues were homogenized by a tissue 
homogenizer in 0.1 mM phosphate‑buffered solution and 
centrifuged at 15,000 g for 15 min at 4°C. Supernatants 
were harvested and stored at −80°C. Protein concentrations 
were measured by using a bicinchoninic acid protein assay 
kit (Beyotime Biotechnology, China) and the level of CCL3/
MIP‑1alpha was measured by ELISA kits (Peprotech, USA) 
according to the instructions. Results are recorded as pg of 
CCL3/MIP‑1alpha/mg of total protein.
Immunohistochemical analysis
Serial sections were used for detection of CCL3/
MIP‑1alpha, ionized calcium‑binding adapter molecule 
1 (Iba1, also mentioned as allograft inflammatory factor 
1), cyclooxygenase‑2 (COX‑2), phosphorylated P38 
MAPK and phosphorylated ERK1/2 immunoreactivity by 
avidin‑biotin‑peroxidase methods. After rinsing, sections 
were blocked in 5% BSA for 1 h and incubated with specific 
primary antibody overnight at 4°C. The following primary 
antibodies were used: goat anti‑MIP‑1alpha (1:100, Santa 
Cruz Biotechnology, USA), rabbit anti‑Iba1 (1:500, Wako, 
USA), rabbit anti‑ phosphorylated P38 MAPK (1:100, 
Cell Signaling Technology), or phosphorylated ERK1/2 
(1:100, Cell Signaling Technology). Subsequently, sections 
were reacted with relevant biotinylated secondary 
antibodies (all used at 1:500, Vector Laboratories, USA) 
for 1 h and avidin‑conjugated peroxidase complex (1:200, 
Vector Laboratories) for 30 min. Peroxidase reactivity 
was developed using 3, 3’‑diaminobenzidine tablet sets 
(ZSGB‑BIO), and the slide was counterstained, dehydrated 
and observed under a light microscope (Olympus, Japan).
Quantification of the immunopositive cells was 
analyzed by a blinded manner as described in our previous 
work (Zhu et al. 2012). Six coronal brain sections from each 
animal were observed for counting at a 200× magnification. 
The number of immunopositive cells was counted twice in 
two differently visual fields of each subfield of hippocampus 
and in six differently visual fields of cortex per section. 
Double‑labeling immunofluorescence
To identify glial cell distributions of CCL3/MIP‑1alpha 
in the brain, double‑labeling immunofluorescence was 
performed as our previously described (Zhu et al. 2012). 
After rinsing, sections were blocked in 5% BSA and 5% 
normal donkey serum in phosphate‑buffered solution for 
1 h, and incubated in primary antibody solution containing 
goat anti‑MIP‑1alpha (1:100, Santa Cruz Biotechnology) 
with mouse anti‑glial fibrillary acidic protein (GFAP) (1:200; 
Chemicon/Millipore, USA) antibody, a specific marker for 
astrocytes, or anti‑Integrin alpha M (OX‑42, also mentioned 
as an iCb3 complement component) (1:100, Serotec, UK) 
antibody, a marker for activated microglia, overnight 
at 4°C. After three washes, sections were incubated in 
a mixture of Alexa 488‑conjugated donkey anti‑goat 
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antibody (1:500, Invitrogen, USA) to label CCL3/MIP‑1alpha 
and Alexa 594‑conjugated donkey anti‑mouse antibody 
(1:500, Invitrogen) to label GFAP‑positive astrocytes, or 
OX‑42‑positive microglia at room temperature for 1 h. 
Processed sections were coverslipped with Fluorescent 
Mounting Media (Beyotime Biotechnology) and examined 
under a laser scanning confocal microscopy with a Bio‑Rad 
MRC 1024 system (Bio‑Rad laboratories, USA). To analyze 
the antibody specify, both primary antibodies were omitted 
during double staining and no labeling was detected.
Western blot assay
The frozen tissues were homogenized with a tissue 
homogenizer in an ice cold lysis buffer. Supernatants were 
collected and protein concentrations were determined 
using a bicinchoninic acid protein assay kit (Beyotime 
Biotechnology). Thirty micrograms of protein were 
separated by 10% SDS‑PAGE and then transferred to 
polyvinylidene fluoride membrane (Millipore). After 
blocking, the membranes were incubated with indicated 
primary antibodies at 4°C overnight. The primary antibodies 
used were as follows: rabbit anti‑ inducible nitric oxide 
synthase (iNOS) (1:500, Santa Cruz Biotechnology), and P38 
MAPK, phosphorylated P38 MAPK, ERK1/2, phosphorylated 
ERK1/2, JNK, phosphorylated JNK, inhibitor of nuclear 
factor‑kappaB (IkappaB) alpha, phosphorylated IkappaB 
alpha, NF‑kappaB/p65, phosphorylated NF‑kappaB/p65 
(all used at 1:1000, Cell Signaling Technology). After three 
washes, the membranes were incubated with the conjugated 
IgG‑horseradish peroxidase (1:1000, ZSGB‑BIO) at room 
temperature for 2 h. Immunoreactivity was detected by 
an enhanced chemiluminescence kit (Millipore) and then 
the images were analyzed using an image analyzer (Alpha 
Innotech, USA). Membranes were reprobed with mouse 
anti‑beta‑actin antibody to serve as a loading control. 
For iNOS, protein abundance was normalized by the total 
content of beta‑actin. For phosphorylated P38 MAPK, 
ERK1/2, JNK, IkappaB alpha and NF‑kappaB/p65, band 
densities were corrected for variations in loading and 
normalized to the corresponding band densities for total 
P38 MAPK, ERK1/2, JNK, IkappaB alpha, and NF‑kappaB/
p65, respectively.
Real‑time PCR
Total RNA was extracted from rat brains using Trizol 
reagent (Invitrogen). Reverse transcription was carried 
out using a Reverse Transcription System (Promega, 
USA). Real‑time PCR was performed using a LightCycler 
2.0 instrument following the instructions (Roche, USA). 
Each reaction in a volume of 20 μl contained 2 μl cDNA, 
10 μl SYBR® Premix Ex TaqTM (Takara, China), 0.4 μl of 
10 μmol/L forward and reverse primers, and 7.2 μl 
nuclease‑free water. The following primers were used：CCL3/
MIP‑1alpha (GenBank accession number NM013025), 
forward: 5’‑GCTCTGGAACGAAGTCTTCTC‑3’, reverse: 
5’‑GAAAGGCTGCTGGTCTCAAA‑3; GAPDH (FQ216837), 
forward: 5’‑CCCTTCATTGACCTCAACTACA‑3’, reverse: 
5’‑GCCAGTAGACTCCACGACATA‑3’. The cycling conditions 
were 95°C for 30 s, followed by 40 cycles at 95°C for 5 s, 60°C 
for 20 s, and 65°C for 15 s. Each sample was run in triplicate. 
The 2(‑Delta Delta ct) method was used to analyze the data. 
The specificity of the PCR products was assessed by Melting 
curve analysis.
Statistical analysis
All data were presented as means ±SD and analyzed by 
nonparametric test. After testing for normal distribution 
of variables, student’s 2‑tail t‑test and one‑way analysis of 
variance (anova) followed by the post hoc least significant 
difference test were used where appropriate. Statistical 
analysis was performed using SPSS 17.0 software (SPSS Inc., 
USA). P<0.05 was considered statistically significant.
RESULT
Upregulation of CCL3/MIP‑1alpha in LPS‑induced 
brain injury
ELISA and immunohistochemistry were performed to 
determine the pattern of CCL3/MIP‑1alpha expression in 
the brain after treatment with LPS. The levels of CCL3/
MIP‑1alpha protein were scarcely detectable in samples from 
normal rats (0.5 ±0.3 pg/mg protein). After LPS treatment, 
the CCL3/MIP‑1alpha levels were increased slightly in the 
brain tissue homogenates at 6 h (20.2±7.5 pg/mg protein) 
compared with that in the normal rats, reaching maximal 
expression at 24 h (194.5±32.7 pg/mg protein), and remained 
elevated at 72 h (86.1±22.6 pg/mg protein). No significant 
differences were observed between the saline‑injected 
controls (0.7±0.3 pg/mg protein) and normal rats (Fig. 1A). 
Immunohistochemistry revealed that CCL3/MIP‑1alpha 
immunoreactivity was barely detectable throughout the 
brain hemispheres of normal rats. At 6 h after LPS, a few 
CCL3/MIP‑1alpha immunoreactive cells were present 
within or near the blood vessels, ventricles, or meninges. 
However, at 24 h, CCL3/MIP‑1alpha immunoreactivity was 
widely disseminated throughout the brain hemispheres, 
especially in the hippocampus, cerebral cortex, and 
amygdala. At 72 h, CCL3/MIP‑1alpha immunoreactivity 
was distributed moderately in these regions (Fig. 1B). High 
magnification showed immunoreactive cells with a glial 
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Fig. 1. Expression of CCL3/MIP‑1alpha in the brain of rats. (A) Quantitative analysis by ELISA demonstrated the protein expression level of CCL3/MIP‑1alpha 
in the brain homogenates from normal rats (Normal), LPS‑treated rats at 6, 24 and 72 h (6 h, 24 h, and 72 h, respectively), and Saline‑injected controls at 
24 h (Saline (24h)) (*p < 0.05, vs. Normal). (B) Representative images showed CCL3/MIP‑1alpha immunoreactivity in hippocampus (Hp), prefrontal cortex 
(Cx) or amygdala (Amy) of rats (scale bars=50 μm). (C) Double‑immunofluorescence staining showed that CCL3/MIP‑1alpha immunoreactivity (green) were 
localized to OX‑42 rather than GFAP‑labeled glial cells (red) in the hippocampus of rats at 24 h after LPS administration.
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morphology. To determine the glial cellular sources of 
CCL3/MIP‑1alpha, the cells were doubly immunostained 
for CCL3/MIP‑1alpha and either OX‑42 or GFAP on samples 
collected from rats 24 h after LPS treatment. Induced 
CCL3/MIP‑1alpha immunoreactivity was expressed 
in OX‑42‑positive microglia rather than GFAP‑labeled 
astrocytes (Fig. 1C).
Effect of anti‑MIP‑1alpha antibody on the 
microglial reaction in LPS‑induced brain injury
To determine the role of CCL3/MIP‑1alpha in the 
microglial reaction in the brains of rats after treatment 
with LPS, we evaluated the effects of an anti‑MIP‑1alpha 
antibody on the number and morphology of microglia in 
two brain areas, the hippocampus and prefrontal cortex.
Immunohistochemistry revealed that Iba1‑ 
‑immunopositive microglia were scattered throughout 
the hippocampus and prefrontal cortex in the 
Saline+IgG rats, displaying a typical ramified shape 
with small somata and thin processes. In the LPS+IgG 
rats, Iba1 immunoreactivity was significantly increased 
24 h after LPS treatment, and remained elevated at 
72 h. However, in the LPS+anti‑MIP‑1alpha rats, the 
neutralizing antibody clearly inhibited the number of 
Iba1‑immunopositive microglia in both brain regions 
compared with that in the corresponding LPS+IgG rats 
(Figs 2A–2C). Assessing the morphological changes in 
microglia is a reasonable way to evaluate the status of 
microglial activation in response to LPS, as reported 
by Hwang and colleagues (2010). A high‑magnification 
analysis showed that the activated microglia had 
adopted an amoeboid morphology with enlarged cell 
Fig. 2. Microglial reactions in LPS‑induced brain injury. (A) Representative images showed the immunoreactivity of Iba1‑labeled microglia and cellular 
morphology in the hippocampus of rats at 24 h (24 h) and 72 h (72 h) after LPS administration (scale bars=100 μm in column 1 and 3, 20 μm in column 2 
and 4). Counting analysis showed the number of Iba1 immunoreactive microglia in hippocampus (Hp) (B) and prefrontal cortex (Cx) (C) of rats (*p<0.05, 
compared with corresponding Saline+IgG rats, #P<0.05, compared with corresponding LPS+IgG rats).
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bodies and coarse processes at 24 h and 72 h after 
LPS treatment. The application of the anti‑MIP‑α 
neutralizing antibody did not alter the morphology 
of the amoeboid microglia in the brain compared 
with that in the corresponding LPS+IgG rats (Fig. 2A, 
column 2 and 4). These results mean that induced 
CCL3/MIP‑1alpha may contribute to the accumulation 
rather than activation of microglia. 
Effect of anti‑MIP‑1alpha antibody on the 
inflammatory response to LPS‑induced  
brain injury
To determine the effects of CCL3/MIP‑1alpha on 
the inflammatory response to LPS, the expression of 
COX‑2 and iNOS was examined in the hippocampus and 
prefrontal cortex of rats 24 h after administration using 
immunohistochemistry and western blot, respectively. 
COX‑2 immunoreactivity was significantly higher in 
both brain areas of the LPS+IgG rats compared with its 
faint expression in the Saline+IgG rats. However, COX‑2 
immunoreactivity was clearly blocked by treatment with 
the anti‑MIP‑α antibody (Fig. 3A). A similar change was 
also observed in the level of iNOS protein, which was 
significantly lower in the LPS+anti‑MIP‑α rats than in the 
LPS+IgG rats (Fig. 3B).
Activation of MAPKs in the LPS‑induced brain 
injury
To determine the potential links between MAPKs 
and CCL3/MIP‑1alpha, we evaluated the expression of 
phosphorylated P38 MAPK, ERK1/2, and JNK in the brain 
with western blot. The levels of P38 MAPK phosphorylation 
were slightly elevated in the brain tissue homogenates 
at 6 h after LPS treatment, and remained high thereafter. 
Similarly, the phosphorylation of ERK1/2 was dramatically 
upregulated during the observation period after treatment 
with LPS. No significant differences were detected in the 
level of phosphorylated JNK between normal rats and 
LPS‑treated rats (Fig. 4A).
We also mapped the distributions of phosphorylated 
P38 MAPK and ERK1/2 with immunohistochemistry. 
In normal rats, only a few cells immunoreactive for 
phosphorylated P38 MAPK were scattered in the brain 
cortex and vessel walls. At 6 h after LPS, phosphorylated 
P38 MAPK immunoreactivity was faintly detected in the 
hippocampal alveus and peripheral cortex. Thereafter, 
Fig. 3. Effect of anti‑MIP‑1alpha antibody on COX‑2 and iNOS expression in the brain of rats. (A) Representative images and histogram showed COX‑2 
immunoreactivity in hippocampus (Hp) and prefrontal cortex (Cx) of rats (scale bar=100 μm; *p<0.05, compared with corresponding Saline+IgG rats; 
#p<0.05, compared with corresponding LPS+IgG rats). (B) Western blot and histograms showed the protein expression level of iNOS in the hippocampus 
(Hp) and prefrontal cortex (Cx) of rats (*p<0.05, vs. Saline+IgG; #p<0.05, vs. LPS+IgG).
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a significant increase in P38 MAPK phosphorylation 
was observed throughout the brain parenchyma and 
ventricular system at 24 h and 72 h (Figs 4B, 4C). Unlike 
phosphorylated P38 MAPK, immunoreactivity for 
phosphorylated ERK1/2 in the normal rat brain was mainly 
localized to large‑body neuronal cells in the peripheral 
cortex and endothelium‑like cells in the vessel walls. After 
LPS treatment, phosphorylated ERK1/2 was progressively 
expressed by neuronal cells in the cerebral cortex and by 
glia‑shaped cells in the hippocampus and cortex (Figs 4B, 
4D). These results suggest the immunostaining for both 
phosphorylated P38 MAPK and phosphorylated ERK1/2 was 
partly coincidental with the distribution of upregulated 
CCL3/MIP‑1alpha.
Fig. 4. Expression of MAPKs in the brain of rats. (A) Western blot and histogram showed the protein expression levels of phosphorylated (p‑) and total 
(T‑) forms of P38 MAPK, ERK1/2 and JNK in the brain from normal rats (Normal), LPS‑treated rats at 6, 24 and 72 h (6, 24 and 72 h, respectively), and 
Saline‑injected controls at 24 h (Saline (24 h)) (*p<0.05, compared with corresponding normal rats). (B) Representative images showed the immunoreactivity 
of phosphorylated (p‑) P38 MAPK and ERK1/2 in the hippocampus of rats (scale bar=100 μm). Counting analysis showed the numbers of phosphorylated 
(p‑) P38 MAPK (C) and ERK1/2 (D) immunoreactive cells in hippocampus of rats (*p<0.05, vs. Normal).
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Inhibition of P38 MAPK and ERK1/2, CCL3/
MIP‑1alpha expression, and the microglial reaction
To determine the roles of P38 MAPK and ERK1/2 in 
CCL3/MIP‑1alpha expression in LPS‑induced brain injury, 
rats were pretreated with the P38 MAPK inhibitor SB203580 
or the ERK1/2 inhibitor PD98059. As shown in Fig. 5A, 
CCL3/MIP‑1alpha mRNA was increased significantly in the 
LPS+DMSO rats compared with that in the Saline+DMSO rats. 
The expression of the CCL3/MIP‑1alpha gene was clearly 
lower in the brain tissues of the both the LPS+SB203580 
and LPS+PD98059 rats than in those of the LPS+DMSO 
rats. An ELISA was used to examine the CCL3/MIP‑1alpha 
concentrations in homogenates of the hippocampi and 
prefrontal cortices from each group 24 h after LPS treatment. 
The levels of CCL3/MIP‑1alpha protein were clearly higher 
in both regions in the LPS+DMSO rats (206.5±31.4 and 
189.6±28.5 pg/mg protein, hippocampus and prefrontal 
cortex, respectively) than in the Saline+DMSO rats (0.7±0.4 and 
0.5±0.3 pg/mg protein, hippocampus and prefrontal cortex, 
respectively). However, the inhibition of P38 MAPK reduced 
the LPS‑induced upregulation of CCL3/MIP‑1alpha (130.5±25.1 
and 122.3±26.8 pg/mg protein, hippocampus and prefrontal 
cortex in LPS+SB203580 rats) compared to the level in the 
LPS+DMSO rats. Similarly, the upregulated expression of CCL3/
MIP‑1alpha was also reduced in response to ERK1/2 inhibition 
in the LPS+PD98059 rats (142.1±21.7 and 118.7±29.4 pg/mg 
protein, hippocampus and prefrontal cortex, respectively) 
compared with that in the LPS+DMSO rats (Figs 5B, 5C). A study 
of the effects of MAPKs on Iba1 immunoreactivity revealed 
that the number of Iba1‑positive cells was clearly lower in the 
brains of both the LPS+SB203580 and LPS+PD98059 rats than in 
the LPS+DMSO rats (Figs 5D, 5E).
Activation of NF‑kappaB, and CCL3/MIP‑1alpha 
expression and microglial accumulation
We investigated the activation of NF‑kappaB by 
evaluating the phosphorylation of both IkappaB alpha and 
Fig. 5. Effects of inhibitors of P38 MAPK and ERK1/2 on CCL3/MIP‑1alpha expression and Iba1 immunoreactivity. (A) Quantitative analysis by real‑time 
PCR showed the CCL3/MIP‑1alpha mRNA expression in the brain tissues of rats, normalized to the levels of GAPDH (*p<0.05, vs. Saline+DMSO, #p<0.05, 
vs. LPS+DMSO). Quantitative analysis by ELISA showed the protein expression level of CCL3/MIP‑1alpha in hippocampus (B) and prefrontal cortex 
(C) of rats (*p<0.05, vs. Saline+DMSO; #p<0.05, vs. LPS+DMSO). (D) Representative images showed Iba1 immunoreactivity in the hippocampus of rats 
(scale bar=100 μm). (E) Counting analysis showed the number of Iba1 immunoreactive cells in hippocampus and prefrontal cortex of rats (*p<0.05, vs. 
Saline+DMSO; #p<0.05, vs. LPS+DMSO).
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NF‑kappaB/p65 subunit in the hippocampus of rats 24 h 
after LPS administration. As shown in Fig. 6A, the protein 
levels of phosphorylated IkappaB alpha and NF‑kappaB/p65 
were clearly higher in the LPS rats than in the Saline rats.
To determine whether NF‑kappaB affects CCL3/
MIP‑1alpha expression, we performed an experiment 
with the NF‑kappaB inhibitor PDTC, administered by i.c.v. 
injection. At the dose used, PDTC successfully inhibited 
LPS‑induced NF‑kappaB/p65 phosphorylation (Fig. 6B). 
NF‑kappaB inhibition also caused reductions in CCL3/
MIP‑1alpha mRNA and protein levels (192.6±30.8 vs. 
130.2±26.5 pg/mg protein, LPS+Saline rats vs. LPS+PDTC 
rats) and in the number of Iba1‑immunoreactive cells 
in the hippocampi of the LPS+PDTC rats compared with 
those in the LPS+Saline rats (Figs 6C–6E). NF‑kappaB may 
also be a signaling molecule downstream from the MAPKs 
(P38 MAPK and ERK1/2) in LPS‑induced brain injury, 
because the levels of phosphorylated NF‑kappaB/p65 were 
significantly lower in the hippocampi of the LPS+SB203580 
and LPS+PD98059 rats than in those of the LPS+DMSO rats 
(Fig. 7).
DISCUSSION
In this study, we have shown that i.c.v. administration 
of LPS caused a marked increase in CCL3/MIP‑1alpha 
protein in the rat brain 6–72 h after treatment. Further 
studies, using an anti‑MIP‑1alpha neutralizing antibody, 
demonstrated that CCL3/MIP‑1alpha affects microglial 
accumulation and the expression of COX‑2 and iNOS 
during LPS‑induced brain injury. We also showed that LPS 
Fig. 6. NF‑kappaB activation, and effect of NF‑kappaB inhibitor on NF‑kappaB/p65 phosphorylation, CCL3/MIP‑1alpha and Iba1 expression in the brain of 
rats. (A) Western blot and histograms showed phosphorylated (p‑) and total (T‑) IkappaB alpha and phosphorylated (p‑) NF‑kappaB/p65 in the hippocampus 
of rats (*p<0.05, compared with corresponding Saline rats). (B) Western blot was performed to measure the expression of phosphorylated (p‑) NF‑kappaB/
p65 in the hippocampus (*p<0.05). (C) Quantitative analysis by real‑time PCR showed the CCL3/MIP‑1alpha mRNA expression in the hippocampus of rats, 
normalized to the levels of GAPDH (*p<0.05, vs. Saline, #p<0.05, vs. LPS+Saline). Histograms showed the level of CCL3/MIP‑1alpha protein by ELISA (D) and 
number of Iba1 immunoreactive cells (E) in hippocampus of rats (*p<0.05, vs. Saline; #p<0.05, vs. LPS+Saline).
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induced the phosphorylation of MAPKs in the observation 
period, and increased the phosphorylation of NF‑kappaB/
p65. Moreover, the inhibition of P38 MAPK, ERK1/2, or 
NF‑kappaB reduced the upregulation of CCL3/MIP‑1alpha 
and microglial accumulation. Therefore, in LPS‑induced 
brain injury, upregulated CCL3/MIP‑1alpha mediates the 
accumulation of microglia and the neuroinflammatory 
response, and CCL3/MIP‑1alpha may be induced under the 
control of the MAPK and NF‑kappaB signaling molecules.
CCL3/MIP‑1alpha, a vital member of the beta‑chemokine 
subfamily, has been implicated in the inflammatory 
processes of various neuropathological conditions, 
including Alzheimer’s disease (Passos et al. 2009), cerebral 
ischemia (Wang et al. 2008), and LPS‑induced endotoxemia 
(Gourmala et al. 1999, Raghavendra Rao et al. 2003). CCL3/
MIP‑1alpha may facilitate the chemotaxis of microglia and 
monocytes through CCR1, CCR4 and CCR5 receptors (Wang 
et al. 2008, Passos et al. 2009). In this study, we observed 
a significant increase of CCL3/MIP‑1alpha protein in the 
cerebral hemispheres 24–72 h after the administration 
of LPS, which is consistent with a previous report by 
Gourmala and others (1999), who demonstrated that 
a pyrogenic dose of LPS caused a time‑dependent increase 
in CCL3/MIP‑1alpha expression, which peaked 12–16 h 
after the intravenous administration of LPS. We also 
investigated the biological function of CCL3/MIP‑1alpha 
in the neuroinflammation caused by LPS in pretreating 
animals with an anti‑MIP‑1alpha antibody, which reduced 
the number of activated microglial cells, but did not modify 
the morphology of the microglia. Such results suggest that 
CCL3/MIP‑1alpha is responsible for the accumulation 
rather than the activation of microglia.
Consistent with previous studies (Gourmala et al. 
1999), double immunostaining demonstrated that CCL3/
MIP‑1alpha immunoreactivity is expressed by OX‑42‑labeled 
microglia but not by GFAP‑labeled astrocytes. These data 
indicate that upregulated CCL3/MIP‑1alpha may act in an 
autoregulatory way to mediate the microglial reaction in 
LPS‑induced brain injury. However, CCL3/MIP‑1alpha has 
also been detected in neurons and astrocytes in the rodent 
brain under other pathological conditions (Wang et al. 2008, 
Xu et al. 2009). These inconsistent results can be partly 
explained by the differences in the species, ages, or types 
of injury investigated. Additionally, OX‑42 antibody could 
recognize blood‑derived monocytes and macrophages as 
well, so some OX‑42‑positive cells may stand for infiltrated 
leukocytes derived from blood. Our results also show 
that the expression of two proinflammatory factors, 
COX‑2 and iNOS, was reduced by pretreatment with the 
anti‑MIP‑1alpha antibody. In a mouse model of Alzheimer’s 
disease, investigators found that CCL3/MIP‑1alpha 
prompted the production of COX‑2 and iNOS after the 
administration of beta‑amyloid (1–40) by regulating AP‑1 
and NF‑kappaB (Passos et al. 2009). These findings suggest 
that CCL3/MIP‑1alpha contributes to the inflammatory 
response in some neuropathological conditions, and that 
the production of cerebral cytokines is not necessarily 
associated with the morphological signs of microglial 
activation (Hanisch 2002). However, a recent report 
demonstrated that CCL3/MIP‑1alpha failed to stimulate 
nitric oxide secretion in rat microglial cultures (Skuljec 
et al. 2011). These contradictory data emphasize the need 
to thoroughly investigate the role of CCL3/MIP‑1alpha in 
regulating the production of COX‑2 and iNOS by glial cells.
MAPKs are serine/threonine kinases, mainly 
including the P38 MAPK, ERK, and c‑JNK families, that 
are widely expressed in many tissues, including the CNS. 
However, there is limited information on the pattern 
of MAPK expression in the brain after LPS treatment or 
bacterial infection (Davis et al. 2000, Ferrer et al. 2001). 
Our results show that the i.c.v. administration of LPS 
induced a time‑dependent increase in phosphorylated 
P38 MAPK and ERK1/2, from 6 h to 72 h after treatment. 
Interestingly, we detected no significant differences in JNK 
phosphorylation among the groups studied. This finding 
may be ascribed to the time‑course of our observations in 
the present study, because these phenomena have been 
detected in rats with traumatic brain injury (Raghupathi et 
al. 2003). A further immunohistochemical analysis showed 
that the distribution of phosphorylated P38 MAPK and 
ERK1/2 in glia‑shaped cells was to some extent consistent 
with CCL3/MIP‑1alpha immunostaining, indicating the 
potential involvement of the MAPK (P38 MAPK and 
ERK1/2) pathways in the induction of CCL3/MIP‑1alpha by 
LPS. Several in vitro studies have verified this assumption 
(Song et al. 2002, Bianchi et al. 2011). However, considering 
the paucity of direct in vivo evidence, we conducted an 
experiment in which rats were pretreated with SB203580 
or PD98059 before LPS‑induced brain injury. The inhibition 
of P38 MAPK or ERK1/2 reduced the upregulation of CCL3/
Fig.  7. Effects of inhibitors of P38 MAPK and ERK1/2 on NF‑kappaB/p65 
phosphorylation. Western blot was performed to measure the protein 
expression level of phosphorylated (p‑) NF‑kappaB/p65 in the hippocampus 
of rats at 24 h after LPS administration (*p<0.05).
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MIP‑1alpha expression and the accumulation of activated 
microglia. To our knowledge, this is the first in vivo study 
to confirm a causative role for P38 MAPK and ERK1/2 in 
signaling events that mediate CCL3/MIP‑1alpha expression 
in microglia after the administration of LPS. In previous 
study using primary microglial cultures, activated P2Y6 
and P2X7 receptors were shown to cause the microglial 
production of CCL3 (Kataoka et al. 2009, Kim et al. 
2011). Moreover, considering several findings showing 
phosphorylation of p38MAPK and ERK1/2 in response 
to activation of P2Y6 and P2X7 (Morioka et al. 2013, Kim 
et al. 2015), it is also speculated MAPKs signaling play an 
important role in production of CCL3 from microglia.
NF‑kappaB is an ubiquitously expressed transcription 
factor that regulates the expression of genes involved in 
a wide range of neuropathological processes, including 
neuroinflammation, trauma, and hypoxia (Nurmi et al. 2004, 
van Loo et al. 2006). The level of phosphorylation of the 
NF‑kappaB inhibitory protein IkappaB in whole‑cell extracts 
can be used as an index of the activity of the NF‑kappaB 
pathway (Hoffmann et al. 2002). In accord with previous 
studies (Wang et al. 2009, Mao et al. 2012), we demonstrated 
that LPS caused a significant increase in the phosphorylation 
of IkappaB alpha in the hippocampus 24 h after treatment. 
Although the phosphorylation of the NF‑kappaB p65 
subunit is also crucial for full NF‑kappaB activation, this 
activation can be incomplete contact with IkappaB alpha 
phosphorylation and degradation (Madrid et al. 2001). Our 
study further showed that LPS induced the phosphorylation 
of the NF‑kappaB/p65 subunit 24 h after injury. Inhibition 
of NF‑kappaB by pretreatment with PDTC not only reduced 
the level of NF‑kappaB/p65 phosphorylation but prevented 
CCL3/MIP‑1alpha expression and microglial accumulation. 
These results confirm the involvement of NF‑kappaB in the 
induction of CCL3/MIP‑1alpha expression after treatment 
with LPS, and hint at the neuroprotective effect of inhibiting 
NF‑kappaB activation.
However, published data have shown that NF‑kappaB 
may have dual roles in some neuropathological processes, 
and its actual roles in many CNS disorders remain 
controversial (van den Tweel et al. 2006, Duckworth 
et al. 2006). The neuroprotective effect of inhibiting 
NF‑kappaB activation demonstrated here could be 
ascribed to our choice of the therapeutic window for 
PDTC treatment. In neonatal hypoxic–ischemic models, 
early NF‑kappaB activation causes brain damage 3–6 h 
after hypoxia–ischemia, but late NF‑kappaB activation 
provides endogenous neuroprotection and upregulates 
the expression of antiapoptotic molecules (Nijboer et al. 
2008). The prolonged period of observation in the present 
study may have allowed fuller information on the role of 
NF‑kappaB in brain damage to be collected. Furthermore, 
the inhibition of both P38 MAPK and ERK1/2 reduced the 
upregulated phosphorylation of NF‑kappaB/p65 after 
LPS treatment, implicating NF‑kappaB as a downstream 
molecule of the MAPKs or at least a cross‑link between 
them. Given the limitations of pharmacological inhibitors 
and the complexity of the in vivo situation, further 
studies are required to provide greater insight into the 
interactions between MAPKs and NF‑kappaB and the 
upstream regulators of MAPKs and NF‑kappaB signaling to 
mediate CCL3/MIP‑1alpha expression in both in vivo and in 
vitro experiments. 
This study demonstrates that CCL3/MIP‑1alpha is 
significantly increased in the brains of rats after the 
administration of LPS, and its upregulation is conducive to 
the accumulation of microglia and the production of both 
COX‑2 and iNOS. The induction of CCL3/MIP‑1alpha is also 
regulated, at least in part, by the MAPK and NF‑kappaB 
signaling molecules. These data may allow the development 
of therapeutic strategies to control the neuroinflammatory 
reaction after brain injury by targeting CCL3/MIP‑α and its 
upstream signaling molecules.
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